BROAD COVERAGE
Most other technologies are restricted to certain target classes, exclude important target classes such as membrane proteins (GPCRs, transporter proteins), or are limited in proteome coverage. In contrast, Retrogenix’s technology does not have these restrictions - it has extensive coverage of the proteome and works well for both membrane and intracellular proteins.
Furthermore, we are not limited to detecting binding at a single binding site (as with competition-based assays). Because our technology detects direct binding of drug to protein, we can discover important allosteric interactions.
RELEVANT
All proteins are human, full-length, and expressed in their native environment (i.e. in human cells). By using tritiated drugs, this avoids structural modifications to the drug which is a requirement for many other technologies. Combined, this ensures that all observed drug-protein interactions are relevant and avoid false negatives and positives common to other approaches.
SENSITIVE
Drug-protein interactions weaker than 0.1 µM are readily detected.
RAPID
At Retrogenix, we can fully profile a test compound in 2-4 weeks.
COST-EFFECTIVE
As well as offering a higher specification technology over competitor technologies, our solution is cost effective, and return on investment will be significant.
